Much-need holiday cheer for Ariad; FDA clears Iclusig’s return
By Jennifer Boggs
Friday, December 20, 2013
Ariad Pharmaceuticals Inc. got a nice holiday gift from the FDA allowing for immediate resumption of sales of leukemia drug Iclusig (ponatinib), two months after it was suspended from the market, and pushing shares of the troubled biotech up 16.5 percent Friday.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.